• news.cision.com/
  • H. Lundbeck A/S/
  • Top line results of phase III study in acute ischemic stroke (DIAS-2) do not demonstrate difference between desmoteplase and placebo
English

Top line results of phase III study in acute ischemic stroke (DIAS-2) do not demonstrate difference between desmoteplase and placebo

Report this content 

                        
PAION AG and US partner Forest Laboratories, Inc. today announced the top line
results of the DIAS-2 (Desmoteplase In Acute Ischemic Stroke) study with the
compound desmoteplase.





                                            

                

            

        

    

    



    

        
 Subscribe

        

            

        

    


        

            
        

        

            
        

        



    

        
 Documents & Links